Chinese Pharma Advances AI-Discovered Drug to Phase III Trials
96Stats · x · 2026-07-14
A Chinese pharmaceutical company has advanced a lung cancer drug—entirely targeted and molecularly designed by AI—into Phase III clinical trials (involving 320名患者).
Additionally, the company invested up to 1.75 亿美元 in developing another brain disease drug based on an AI-identified mechanism. This indicates a shift in Chinese pharma procurement models: moving from simply subscribing to AI software tools to directly purchasing AI-generated biological hypotheses and outcomes.
Related event: AI-Discovered Drug Enters Phase III Trials in China(2 posts)→
More from Research
- Robotics-friendly FBA deformable solver lands in PranaLabs' newton engine — ChongZzZhang · 2026-10-26
- FLASH: GPU-native deformable sim learns cloth folding in minutes on one RTX 5090 — ChongZzZhang · 2026-10-26
- LEMON: zero-shot LLM misbehavior monitor flags hallucinations from attention maps — yoavartzi · 2026-10-26
- Behind the EMNLP keynote: LMs as simulated learners to generate child language acquisition hypotheses — najoungkim · 2026-10-26
- The paper behind the EMNLP 2026 keynote on bigram 'simulated learners' — najoungkim · 2026-10-26
- Laying out DeepLIFT as a standalone computation graph: from sequence to attributions directly — jmschreiber91 · 2026-10-26